Immune activation and arterial stiffness in lean adults with HIV on antiretroviral therapy.
antiretroviral therapy
arterial stiffness
endothelial dysfunction
immune activation
lean adults
Journal
Southern African journal of HIV medicine
ISSN: 2078-6751
Titre abrégé: South Afr J HIV Med
Pays: South Africa
ID NLM: 100965417
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
11
2020
accepted:
02
12
2020
entrez:
7
4
2021
pubmed:
8
4
2021
medline:
8
4
2021
Statut:
epublish
Résumé
Greater T-cell activation was associated with reduced vascular compliance amongst persons living with HIV (PLWH) especially among overweight and obese individuals. There is a paucity of data regarding immune activation and arterial stiffness amongst PLWH in sub-Saharan Africa (SSA). To determine the association between immune activation and arterial stiffness in lean PLWH in SSA. Forty-eight human immunodeficiency virus positive (HIV+) adults on antiretroviral therapy (ART) >5 years and 26 HIV-negative adults, all with BMI < 25 kg/m Increased immune activation was observed in the CD4+ and CD8+ T cells of PLWH, 16.7% vs. 8.9% and 22.0% vs. 12.4% respectively; Our population of lean PLWH had increased immune activation and higher cfAiX, a marker of arterial stiffness, compared to HIV-negative persons. The negative association between immune activation and arterial stiffness as measured by crPWV in PLHW on long-term treatment needs further elucidation.
Sections du résumé
BACKGROUND
BACKGROUND
Greater T-cell activation was associated with reduced vascular compliance amongst persons living with HIV (PLWH) especially among overweight and obese individuals. There is a paucity of data regarding immune activation and arterial stiffness amongst PLWH in sub-Saharan Africa (SSA).
OBJECTIVE
OBJECTIVE
To determine the association between immune activation and arterial stiffness in lean PLWH in SSA.
METHOD
METHODS
Forty-eight human immunodeficiency virus positive (HIV+) adults on antiretroviral therapy (ART) >5 years and 26 HIV-negative adults, all with BMI < 25 kg/m
RESULTS
RESULTS
Increased immune activation was observed in the CD4+ and CD8+ T cells of PLWH, 16.7% vs. 8.9% and 22.0% vs. 12.4% respectively;
CONCLUSION
CONCLUSIONS
Our population of lean PLWH had increased immune activation and higher cfAiX, a marker of arterial stiffness, compared to HIV-negative persons. The negative association between immune activation and arterial stiffness as measured by crPWV in PLHW on long-term treatment needs further elucidation.
Identifiants
pubmed: 33824734
doi: 10.4102/sajhivmed.v22i1.1190
pii: HIVMED-22-1190
pmc: PMC8008040
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1190Subventions
Organisme : FIC NIH HHS
ID : D43 TW009744
Pays : United States
Organisme : NHLBI NIH HHS
ID : K01 HL130497
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI110527
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024975
Pays : United States
Informations de copyright
© 2021. The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Références
BMC Public Health. 2018 Oct 11;18(1):1168
pubmed: 30309337
Cardiovasc Diabetol. 2014 Oct 22;13:141
pubmed: 25331525
Atherosclerosis. 2011 Jul;217(1):207-13
pubmed: 21492857
Blood. 2004 Aug 15;104(4):942-7
pubmed: 15117761
AIDS Res Hum Retroviruses. 2017 Feb;33(2):181-186
pubmed: 27527002
Physiol Rev. 2019 Jan 1;99(1):311-379
pubmed: 30379623
Clin Exp Immunol. 1994 Jul;97(1):83-6
pubmed: 8033424
Front Immunol. 2019 Feb 26;10:291
pubmed: 30863403
J Neuroimmune Pharmacol. 2015 Mar;10(1):111-21
pubmed: 25575491
Curr Hypertens Rep. 2019 Jun 4;21(7):56
pubmed: 31165257
Lancet Diabetes Endocrinol. 2019 Mar;7(3):231-240
pubmed: 30704950
Clin Exp Hypertens. 2011;33(8):511-7
pubmed: 21958364
PLoS One. 2016 Apr 25;11(4):e0153456
pubmed: 27111769
Aging Cell. 2016 Apr;15(2):389-92
pubmed: 26696322
J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):349-56
pubmed: 25314253
Eur Heart J. 2013 May;34(19):1432-6
pubmed: 23335603
J Infect Dis. 2016 Oct 1;214 Suppl 2:S75-82
pubmed: 27625434
J Am Soc Hypertens. 2014 Jan;8(1):28-35
pubmed: 24503235
Circulation. 2018 Sep 11;138(11):1100-1112
pubmed: 29967196
Afr Health Sci. 2018 Sep;18(3):512-522
pubmed: 30602982
Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2792-804
pubmed: 18456725
J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27
pubmed: 20338492
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
Sci Rep. 2018 May 8;8(1):7227
pubmed: 29740045
PLoS One. 2019 Apr 18;14(4):e0215620
pubmed: 30998801
Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2276-83
pubmed: 17823366
Obes Res. 2003 Nov;11(11):1278-89
pubmed: 14627747
Drugs. 2016 Apr;76(5):533-49
pubmed: 26915027
Vasc Health Risk Manag. 2013;9:509-16
pubmed: 24043942
Immunol Rev. 2013 Jul;254(1):78-101
pubmed: 23772616
Free Radic Biol Med. 2012 Jul 1;53(1):143-59
pubmed: 22564529
J Infect Dis. 2011 Feb 15;203(4):452-63
pubmed: 21220772
Glob Heart. 2020 Feb 12;15(1):15
pubmed: 32489788
HIV Med. 2013 Jul;14(6):385-90
pubmed: 23332012
AIDS. 2016 Jun 1;30(9):1363-73
pubmed: 26990630
BMC Infect Dis. 2020 Jul 3;20(1):473
pubmed: 32620082
Circulation. 2010 Feb 2;121(4):505-11
pubmed: 20083680
J Biomed Biotechnol. 2009;2009:749575
pubmed: 19884983
Clin Infect Dis. 2017 Oct 15;65(8):1266-1271
pubmed: 28605504
AIDS. 2016 Jun 19;30(10):1495-509
pubmed: 27058351